Last reviewed · How we verify

Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge

University of Wisconsin, Madison · FDA-approved active Small molecule Quality 17/100

The combination of Cessation Phase Nicotine Patch and Nicotine Mini-Lozenge is a smoking cessation therapy developed by the University of Wisconsin, Madison. This dual-therapy approach aims to reduce nicotine withdrawal symptoms and cravings by providing a steady dose of nicotine through the patch and additional doses via lozenges as needed. The treatment is designed to help smokers gradually reduce their dependence on cigarettes. While there is no FDA label, the therapy has shown promise in clinical trials and is being evaluated for broader use. Common side effects include nausea, headache, and dizziness, which are generally mild to moderate in severity.

At a glance

Generic nameCessation Phase Nicotine Patch + Nicotine Mini-Lozenge
Also known asCessation Phase Combination NRT
SponsorUniversity of Wisconsin, Madison
Drug classNicotine replacement therapy (NRT)
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: